Broker Ratings

Merck & Co., Inc. Share Price Target ‘$142.98’, now 8.7% Upside Potential

Merck & Co., Inc. which can be found using ticker (MRK) have now 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $155.00 and $124.50 calculating the average target share price we see $142.98. (at the time of writing). Now with the previous closing price of $131.50 this indicates there is a potential upside of 8.7%. It’s also worth noting that there is a 50 day moving average of $129.23 and the 200 day MA is $117.70. The total market capitalization for the company now stands at 328.81B. The stock price is currently at: $129.82 USD

The potential market cap would be $357,514,601,578 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 144.24, revenue per share of $24.22 and a 10.26% return on assets.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Merck & Co., Inc. (MRK) Investor Outlook: Analyzing a 18.35% Potential Upside with Strong Dividend Yields

    Merck & Co., Inc. (NYSE: MRK), a stalwart in the healthcare sector, continues to capture investor attention with its robust pharmaceutical portfolio and promising growth prospects. Headquartered in Rahway, New

    Merck & Company, Inc. (MRK) Stock Analysis: Evaluating a 16.40% Potential Upside for Investors

    Merck & Company, Inc. (NYSE: MRK), a stalwart in the healthcare sector, commands a market cap of $218.53 billion and holds a prominent position in the drug manufacturing industry. With

    Merck & Company, Inc. (MRK) Stock Analysis: Exploring a 20% Potential Upside for Investors

    As a cornerstone of the healthcare sector, Merck & Company, Inc. (NYSE: MRK) stands out in the pharmaceutical industry with a robust array of products and a rich history dating

    Merck & Company, Inc. (MRK) Stock Analysis: Navigating a 17.92% Potential Upside in the Healthcare Sector

    Merck & Company, Inc. (NYSE: MRK) stands as a towering presence in the healthcare sector, particularly within the drug manufacturing industry. With a substantial market capitalization of $214.78 billion, this

    Merck & Company, Inc. (MRK) Stock Analysis: Evaluating a 13.92% Potential Upside in the Healthcare Sector

    As one of the stalwarts in the healthcare industry, Merck & Company, Inc. (NYSE: MRK) remains an attractive proposition for investors with its robust pharmaceutical portfolio and potential upside. With

    Merck & Company, Inc. (MRK) Stock Analysis: A 29% Upside Potential Amid Strong Dividends

    Merck & Company, Inc. (NYSE: MRK), a stalwart in the healthcare sector, is capturing investor attention with its combination of robust dividends and a notable upside potential. With a market

      Search

      Search